PARP Inhibitor (Olaparib) in men with BRCA mutations and prostate cancer

A recent study found that Olaparib (Lynparza) improved survival outcomes among men with BRCA1/2 mutations and metastatic castration-resistant prostate cancer, regardless of whether the mutation was germline or somatic. This underscores the potential of targeted therapies in improving outcomes for those with inherited cancer gene mutations.

Learn more at:

Reference: Mateo, et al. J Clin Oncol. 2024;42(5):571-583. PMID: 37963304.

Permanent link to this article: